Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Iron sucrose
Accession Number
DB09146  (DB06790)
Type
Small Molecule
Groups
Approved
Description

Iron sucrose (sucroferric oxyhydroxide or iron saccharate) is used as a source of iron in patients with iron deficiency anemia with chronic kidney disease (CKD), including those who are undergoing dialysis (hemodialysis or peritoneal) and those who do not require dialysis. Due to less side effects than iron dextran, iron sucrose is more preferred in chronic kidney disease patients.

Structure
Thumb
Synonyms
  • Ferric hydroxide sucrose complex
  • Iron oxide saccharated
  • Iron saccharate
  • Iron sucrose
  • Iron sucrose complex
  • Iron sugar
  • Iron(III) hydroxide sucrose complex
  • Saccharated ferric oxide
  • Saccharated iron
  • Saccharated iron oxide
  • Sucroferric oxyhydroxide
External IDs
XI 921
Active Moieties
NameKindUNIICASInChI Key
IronunknownE1UOL152H77439-89-6XEEYBQQBJWHFJM-UHFFFAOYSA-N
Ferric cationionic91O4LML61120074-52-6VTLYFUHAOXGGBS-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
VelphoroTablet, chewable500 mgOralVifor Fresenius Medical Care Renal Pharma LtdNot applicableNot applicableCanada
VenoferInjection, solution20 mg/1mLIntravenousAMERICAN REGENT, INC.2011-01-27Not applicableUs
VenoferInjection, solution20 mg/1mLIntravenousFresenius Medical Care Holdings, Inc.2008-11-04Not applicableUs
VenoferInjection, solution20 mg/1mLIntravenousFresenius Medical Care Holdings, Inc.2011-01-27Not applicableUs
VenoferInjection, solution20 mg/1mLIntravenousAMERICAN REGENT, INC.2007-06-12Not applicableUs
VenoferInjection75 mg/3.75mLIntravenousFresenius Medical Care North America2000-11-062010-12-22Us
VenoferInjection, solution20 mg/1mLIntravenousAMERICAN REGENT, INC.2000-11-10Not applicableUs
VenoferInjection, solution20 mg/1mLIntravenousFresenius Medical Care North America2008-11-042011-06-30Us
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Myferon 150Capsule150 mg/1OralMartin Ekwealor Pharmaceuticals, Inc.1996-12-01Not applicableUs
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Bal-Care DHAIron sucrose (1.35 mg/1) + Ascorbic acid (120 mg/1) + Beta carotene (2850 [iU]/1) + Calcium carbonate (219 mg/1) + Cholecalciferol (840 [iU]/1) + Cupric oxide (2 mg/1) + Cyanocobalamin (.012 mg/1) + DL-alpha tocopheryl acetate (3 mg/1) + Folic acid (1 mg/1) + Iodine (.223 mg/1) + Magnesium oxide (25 mg/1) + Nicotinamide (20 mg/1) + Omega-3 fatty acids (430 mg/1) + Pyridoxine hydrochloride (50 mg/1) + Riboflavin (4 mg/1) + Sodium feredetate (25.65 mg/1) + Thiamine mononitrate (1.8 mg/1) + Zinc oxide (25 mg/1)KitOralPru Gen Pharmaceuticals2012-05-01Not applicableUs
Bal-Care DHA EssentialIron sucrose (1.35 mg/1) + Ascorbic acid (120 mg/1) + Beta carotene (2850 [iU]/1) + Calcium carbonate (219 mg/1) + Cholecalciferol (840 [iU]/1) + Cupric oxide (2 mg/1) + Cyanocobalamin (.012 mg/1) + DL-alpha tocopheryl acetate (3 mg/1) + Folic acid (1 mg/1) + Iodine (.223 mg/1) + Magnesium oxide (25 mg/1) + Nicotinamide (20 mg/1) + Omega-3 fatty acids (374 mg/1) + Pyridoxine hydrochloride (50 mg/1) + Riboflavin (4 mg/1) + Sodium feredetate (25.65 mg/1) + Thiamine mononitrate (1.8 mg/1) + Zinc oxide (25 mg/1)KitOralPru Gen Pharmaceuticals2012-05-01Not applicableUs
Choice OB DHAIron sucrose (29 mg/1) + Ascorbic acid (60 mg/1) + Beta carotene (1700 [iU]/1) + Cholecalciferol (400 [iU]/1) + Cyanocobalamin (5 ug/1) + DL-alpha tocopheryl acetate (30 [iU]/1) + Doconexent (250 mg/1) + Folic acid (1 mg/1) + Magnesium oxide (25 mg/1) + Nicotinamide (15 ug/1) + Pyridoxine hydrochloride (2.5 mg/1) + Riboflavin (1.8 mg/1) + Thiamine mononitrate (1.6 mg/1) + Zinc oxide (15 mg/1)KitOralAcella Pharmaceuticals, LLC2013-05-172015-07-31Us
HemeNatal OBIron sucrose (28 mg/1) + Biotin (30 ug/1) + Cholecalciferol (400 [iU]/1) + Cupric sulfate pentahydrate (.8 mg/1) + Cyanocobalamin (12 ug/1) + Folic acid (1 mg/1) + Heme iron polypeptide (6 mg/1) + Nicotinamide (17 mg/1) + Calcium pantothenate (10 mg/1) + Potassium Iodide (250 ug/1) + Pyridoxine hydrochloride (50 mg/1) + Riboflavin (1.6 mg/1) + Sodium selenate (65 ug/1) + Thiamine mononitrate (1.5 mg/1) + Zinc oxide (4.5 mg/1) + alpha-Tocopherol succinate (10 [iU]/1)TabletOralWh Nutritionals, Llc2012-03-08Not applicableUs
HemeNatal OB plus DHAIron sucrose (28 mg/1) + Biotin (30 ug/1) + Cholecalciferol (400 [iU]/1) + Cupric sulfate pentahydrate (0.8 mg/1) + Cyanocobalamin (12 ug/1) + Doconexent (200 mg/1) + Folic acid (1 mg/1) + Heme iron polypeptide (6 mg/1) + Nicotinamide (17 mg/1) + Osbond acid (2.5 mg/1) + Calcium pantothenate (10 mg/1) + Potassium Iodide (250 ug/1) + Pyridoxine hydrochloride (50 mg/1) + Riboflavin (1.6 mg/1) + Sodium selenate (65 ug/1) + Thiamine mononitrate (1.5 mg/1) + Zinc oxide (4.5 mg/1) + alpha-Linolenic acid (0.5 mg/1) + alpha-Tocopherol succinate (10 [iU]/1)KitOralWh Nutritionals, Llc2012-03-082019-04-30Us
HemetabIron sucrose (22 mg/1) + Cyanocobalamin (25 ug/1) + Folic acid (1 mg/1) + Heme iron polypeptide (6 mg/1)TabletOralWh Nutritionals, Llc2012-05-012020-02-28Us
Marnatal FIron sucrose (60 mg/1) + Ascorbic acid (100 mg/1) + Calcium carbonate (150 mg/1) + Cholecalciferol (400 [iU]/1) + Cupric oxide (2 mg/1) + Cyanocobalamin (12 ug/1) + D-alpha-Tocopherol acetate (30 [iU]/1) + Folic acid (1000 ug/1) + Magnesium oxide (25 mg/1) + Nicotinamide (20 mg/1) + Pyridoxine hydrochloride (5 mg/1) + Riboflavin (3.4 mg/1) + Thiamine mononitrate (3 mg/1)CapsuleOralMarnel Pharmaceuticals, Llc2010-01-08Not applicableUs
Myferon 150Iron sucrose (150 mg/1)CapsuleOralMartin Ekwealor Pharmaceuticals, Inc.1996-12-01Not applicableUs
Myferon 150 ForteIron sucrose (150 mg/1) + Cyanocobalamin (25 ug/1) + Folic acid (1 mg/1)CapsuleOralMartin Ekwealor Pharmaceuticals, Inc.1996-12-01Not applicableUs
PNV-FirstIron sucrose (29 mg/1) + Ascorbic acid (30 mg/1) + Beta carotene (1100 [iU]/1) + Cholecalciferol (1000 [iU]/1) + Cupric oxide (2 mg/1) + Cyanocobalamin (12 ug/1) + DL-alpha tocopheryl acetate (20 [iU]/1) + Folic acid (1 mg/1) + Magnesium oxide (20 mg/1) + Nicotinamide (15 mg/1) + Omega-3 fatty acids (200 mg/1) + Potassium Iodide (150 ug/1) + Pyridoxine hydrochloride (2.5 mg/1) + Riboflavin (1.8 mg/1) + Thiamine mononitrate (1.6 mg/1) + Zinc oxide (25 mg/1)Tablet, coatedOralAcella Pharmaceuticals, LLC2013-05-172015-06-30Us
International/Other Brands
Colliron IV / Encifer / Fe-back / Feojectin / Ferijet / Ferosoft S / Ferplex SS / Ferrivenin
Categories
UNII
FZ7NYF5N8L
CAS number
8047-67-4
Weight
Average: 866.546
Monoisotopic: 866.764181
Chemical Formula
C12H29Fe5Na2O23
InChI Key
FWZTTZUKDVJDCM-CEJAUHOTSA-M
InChI
InChI=1S/C12H22O11.5Fe.2Na.4H2O.8O/c13-1-4-6(16)8(18)9(19)11(21-4)23-12(3-15)10(20)7(17)5(2-14)22-12;;;;;;;;;;;;;;;;;;;/h4-11,13-20H,1-3H2;;;;;;;;4*1H2;;;;;;;;/q;5*+3;2*+1;;;;;8*-2/p-1/t4-,5-,6-,7-,8+,9-,10+,11-,12+;;;;;;;;;;;;;;;;;;;/m1.................../s1
IUPAC Name
pentairon(3+) ion disodium (2R,3R,4S,5S,6R)-2-{[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol trihydrate hydroxide octaoxidandiide
SMILES
O.O.O.[OH-].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O

Pharmacology

Indication

Iron sucrose is elemental iron as an injection. It replenishes body iron stores in patients with iron deficiency.

Associated Conditions
Pharmacodynamics

Significant increases in serum iron and serum ferritin and significant decreases in total iron binding capacity occurred four weeks from the initiation of iron sucrose treatment.

Mechanism of action

Following intravenous administration, iron sucrose is dissociated into iron and sucrose and the iron is transported as a complex with transferrin to target cells including erythroid precursor cells. The iron is then incorporated into hemoglobin as the cells mature into red blood cells.

TargetActionsOrganism
AHemoglobin subunit alpha
component of
Humans
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

The intravensously administered iron sucrose injection would result rapidly in high serum iron levels. Maximum measured levels occured after 10 min of injection with an average of 30.00 mg/l.

Volume of distribution

Vd is 7.3 L

Protein binding

It binds with transferrin.

Metabolism

Following IV administration, dissociated into iron and sucrose by the reticuloendothelial system.

Route of elimination

Renal elimination of iron contributed very little to the total elimination (in average less than 5%). While, renal elimination of sucrose accounts for 68-75% of the administered dose after 4 and 24 hours respectively.

Half life

6 hours.

Clearance

Total body clearance is 20.5 ml/min.

Toxicity

Hypersensitivity reactions, including anaphylactic shock, loss of consciousness, collapse, hypotension, dyspnea, and seizure. Monitor iron toxicity through the periodic evaluation of lab works which monitor the body concentration of iron. Lab monitoring of the following parameters: transferrin saturation, serum ferritin concentrations, hemoglobin, and hematocrit could be helpful to avoid iron overload. Severe allergic symptoms include: rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue; unusual hoarseness); burning or pain at the injection site; burning, numbness, or tingling; chest pain; fainting; loss of consciousness; severe or persistent dizziness, headache, or light-headedness; seizures; shortness of breath; swelling of the hands, ankles, or feet.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
3-Aza-2,3-Dihydrogeranyl DiphosphateIron sucrose can cause a decrease in the absorption of 3-Aza-2,3-Dihydrogeranyl Diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Alendronic acidIron sucrose can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.
AlmasilateAlmasilate can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.
AloglutamolAloglutamol can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.
AluminiumAluminium can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminium phosphateAluminium phosphate can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.
AsenapineAsenapine can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. monograph [Link]
  2. article [Link]
External Links
PubChem Compound
91663255
PubChem Substance
310265059
ChemSpider
32699616
ChEMBL
CHEMBL1200823
Wikipedia
Iron_sucrose
ATC Codes
B03AB02 — Saccharated iron oxideV03AE05 — Sucroferric oxyhydroxide
AHFS Codes
  • 40:18.19 — Phosphate-removing Agents

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableHealthy Volunteers1
1CompletedBasic ScienceChronic Renal Failure (CRF) / Iron-Deficiency Anemias1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedPreventionAcute Renal Failure (ARF)1
1CompletedTreatmentHealthy Volunteers1
1Not Yet RecruitingPreventionAcute Kidney Injury (AKI)1
1RecruitingTreatmentBioequivalance1
1WithdrawnPreventionAcute Kidney Injury (AKI)1
1WithdrawnTreatmentFunctional Iron Deficiency / ICU Anemia1
1, 2TerminatedTreatmentPostural Orthostatic Tachycardia Syndrome (POTS)1
1, 2Unknown StatusTreatmentChronic Heart Failure (CHF) / Heart Diseases / Iron-Deficiency Anemias1
2CompletedDiagnosticEndstage Renal Disease1
2CompletedTreatmentAnemias / Iron Deficiency / Kidney Diseases1
2CompletedTreatmentIron Deficiency Anemia (IDA)1
2CompletedTreatmentRestless Legs Syndrome (RLS)1
2RecruitingTreatmentAnemia of Chronic Disease / Hip Arthropathy / Iron Deficiency Anemia (IDA) / Knee Arthropathy1
2SuspendedTreatmentPulmonary Hypertension (PH)1
2TerminatedTreatmentAnemias / Unexplained Anemia (UAE)1
2WithdrawnTreatmentAnemias / Functional Iron Deficiency / Traumas1
2WithdrawnTreatmentInflammatory Bowel Diseases (IBD) / Iron Deficiency Anemia (IDA)1
2WithdrawnTreatmentIron Deficiency1
2, 3CompletedTreatmentAnemias / Renal Failure1
2, 3CompletedTreatmentHaematological Malignancies1
2, 3Unknown StatusTreatmentAnemias / Heart Failure1
3CompletedOtherAnemias2
3CompletedTreatmentAnemias3
3CompletedTreatmentAnemias / Crohn's Disease (CD) / Inflammatory Bowel Diseases (IBD) / Iron Deficiency / Iron-Deficiency Anemias / Ulcerative Colitis1
3CompletedTreatmentAnemias / Renal Failure1
3CompletedTreatmentChronic Kidney Disease Stage 5 (Dialysis Dependent)1
3CompletedTreatmentImpaired Renal Function / Iron Deficiency Anemia (IDA)1
3CompletedTreatmentIron Deficiency Anemia (IDA)6
3CompletedTreatmentIron-Deficiency Anemias / Weight Loss1
3RecruitingTreatmentChronic Kidney Disease Requiring Chronic Dialysis / Hyperphosphataemia1
3RecruitingTreatmentChronic Kidney Disease; Iron Deficiency Anemia1
3RecruitingTreatmentIron Deficiency Anemia (IDA)1
3TerminatedTreatmentHyperphosphataemia1
3WithdrawnTreatmentAnemias / Chronic Heart Failure (CHF) / Chronic Kidney Disease (CKD)1
4Active Not RecruitingTreatmentAnemia of Chronic Kidney Disease1
4Active Not RecruitingTreatmentAnemias / Hemodialysis Treatment1
4CompletedDiagnosticAnemia in Chronic Renal Disease1
4CompletedDiagnosticAnemias / Chronic Renal Failure (CRF)1
4CompletedTreatmentAnemias2
4CompletedTreatmentAnemias / Chronic Kidney Disease (CKD)1
4CompletedTreatmentAnemias / Complications, Pregnancy1
4CompletedTreatmentAnemias / Puerperal Disorders1
4CompletedTreatmentChronic Kidney Disease (CKD) / Heart Failure / Iron Deficiency1
4CompletedTreatmentChronic Renal Failure (CRF) / Iron-Deficiency Anemias1
4CompletedTreatmentInflammatory Bowel Diseases (IBD) / Iron Deficiency1
4CompletedTreatmentIron Deficiency Anemia (IDA)1
4CompletedTreatmentThe Treatment of Iron Deficiency Anemia in Patients With Chronic Kidney Disease1
4Not Yet RecruitingTreatmentHyperphosphataemia / Hypoalbuminemia / Peritoneal dialysis complication1
4Not Yet RecruitingTreatmentOsteoarthritis (OA)1
4RecruitingSupportive CareAnemia of Chronic Kidney Disease1
4SuspendedTreatmentIron Deficiency Anemia (IDA) / Perioperative Blood Conservation1
4Unknown StatusPreventionHip Fractures / Surgical Intervention1
4Unknown StatusTreatmentChronic Renal Failure (CRF)1
4Unknown StatusTreatmentIron Deficiency Anemia (IDA) / Neoplasms, Colorectal1
4Unknown StatusTreatmentPreterm Anemia1
4WithdrawnTreatmentIron Deficiency Anemia (IDA)1
Not AvailableCompletedNot AvailableChronic Heart Failure (CHF) / Chronic Kidney Disease (CKD) / Iron Deficiency Anemia (IDA)1
Not AvailableCompletedNot AvailableHyperphosphataemia1
Not AvailableCompletedBasic ScienceAnemias / Systemic Inflammatory Process1
Not AvailableCompletedBasic ScienceMountain Sickness / Pulmonary Hypertension (PH)1
Not AvailableCompletedPreventionAnemias / Transfusions1
Not AvailableCompletedTreatmentICU Anemia / Traumas1
Not AvailableNot Yet RecruitingNot AvailableIron Deficiency Anemia (IDA)2
Not AvailableRecruitingNot AvailableHyperphosphataemia1
Not AvailableRecruitingTreatmentIron Deficiency Anemia Treatment1
Not AvailableRecruitingTreatmentNeoplasms, Lung / Segmentectomy;Intersegmental Plane1
Not AvailableTerminatedOtherAnemias / End Stage Renal Disease (ESRD)1
Not AvailableTerminatedTreatmentIron-Deficiency Anemias1
Not AvailableUnknown StatusTreatmentRenal Failure Chronic Requiring Hemodialysis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
KitOral
TabletOral
CapsuleOral
CapsuleOral150 mg/1
Suspension / dropsOral
Tablet, coatedOral
Capsule, liquid filledOral
Tablet, chewableOral500 mg
InjectionIntravenous75 mg/3.75mL
Injection, solutionIntravenous20 mg/1mL
Tablet, film coatedOral
Capsule, gelatin coatedOral
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6174442No2001-01-162016-12-19Us
US9561251No2017-02-072030-01-23Us
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility9.52 mg/mLALOGPS
logP1.99ALOGPS
logP-4.5ChemAxon
logS-1.8ALOGPS
pKa (Strongest Acidic)11.84ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count11ChemAxon
Hydrogen Donor Count8ChemAxon
Polar Surface Area189.53 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity68.77 m3·mol-1ChemAxon
Polarizability30.97 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as o-glycosyl compounds. These are glycoside in which a sugar group is bonded through one carbon to another group via a O-glycosidic bond.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
O-glycosyl compounds
Alternative Parents
Disaccharides / C-glycosyl compounds / Ketals / Oxanes / Tetrahydrofurans / Secondary alcohols / Polyols / Oxacyclic compounds / Organic transition metal salts / Primary alcohols
show 5 more
Substituents
C-glycosyl compound / Disaccharide / O-glycosyl compound / Ketal / Oxane / Tetrahydrofuran / Secondary alcohol / Organoheterocyclic compound / Acetal / Polyol
show 12 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Component of
General Function
Oxygen transporter activity
Specific Function
Involved in oxygen transport from the lung to the various peripheral tissues.
Gene Name
HBA1
Uniprot ID
P69905
Uniprot Name
Hemoglobin subunit alpha
Molecular Weight
15257.405 Da
References
  1. monograph [Link]

Carriers

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
Carrier
General Function
Transferrin receptor binding
Specific Function
Transferrins are iron binding transport proteins which can bind two Fe(3+) ions in association with the binding of an anion, usually bicarbonate. It is responsible for the transport of iron from si...
Gene Name
TF
Uniprot ID
P02787
Uniprot Name
Serotransferrin
Molecular Weight
77063.195 Da
References
  1. Horl WH: Iron therapy for renal anemia: how much needed, how much harmful? Pediatr Nephrol. 2007 Apr;22(4):480-9. Epub 2007 Jan 6. [PubMed:17206511]

Drug created on October 01, 2015 10:49 / Updated on November 14, 2019 19:59